Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 1/20 | 0.52 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.47 |
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 3/20 | 0.45 |
| ▸ | RAB9A | P51151 | 3/20 | 0.45 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.44 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.44 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.44 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.44 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.44 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.44 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.42 |
| ▸ | NQO2 | P16083 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3971732 | 1.00 | SRC (0.52) | SRCPLA2G7NFE2L2NPC1RAB9A | |
| SCHEMBL13398097 | 1.00 | SRC (0.52) | SRCPLA2G7NFE2L2NPC1RAB9A | |
| SCHEMBL13397720 | 0.88 | SRC (0.61) | SRCNPC1RAB9AGRIN2DGRIN3B | |
| SCHEMBL3357693 | 0.79 | NPC1 (0.58) | SRCNPC1RAB9AGRIN2DGRIN3B | |
| SCHEMBL6871468 | 0.79 | NPC1 (0.58) | SRCNPC1RAB9AGRIN2DGRIN3B | |
| SCHEMBL6077468 | 0.77 | GRIN2D (0.53) | SRCRAB9AGRIN2DGRIN3BGRIN1 | |
| SCHEMBL5105871 | 0.77 | SRC (0.52) | SRCNPC1RAB9ASMN1; SMN2GAA | |
| SCHEMBL12756974 | 0.77 | MAOB (0.52) | SRCGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL13128152 | 0.77 | SRC (0.47) | SRCNFE2L2NPC1RAB9ACYP1A2 | |
| SCHEMBL9841035 | 0.77 | SRC (0.52) | SRCNQO2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130012546-A1 | FUNGICIDE HYDROXIMOYL-TETRAZOLE DERIVATIVES | BAYER CROPSCIENCE AG (DE) | 2013-01-10 | — | — | US | disclosed |
| US-7507838-B2 | Process for the preparation of Z-5-carboxymethylene-1,3-dioxolan-4-ones | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-03-24 | — | — | US | disclosed |
| EP-1784395-A1 | PROCESS FOR THE PREPARATION OF Z-5-CARBOXYMETHYLENE-1,3-DIOXOLAN-4-ONES | Bristol-Myers Squibb Company (US) | 2007-05-16 | — | — | EP | disclosed |
| US-7109186-B2 | 4-hydroxy-5-oxo-1-(2-[4-methylpiperazin-1-yl]ethyl)-2,5-dihydro-1H-pyrrole-3-carboxylic acid (3,4-dichlorobenzyl)-methyl-amide for human immunodeficiency virus (HIV) treatment | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-09-19 | — | — | US | disclosed |
| WO-2006028733-A1 | PROCESS FOR THE PREPARATION OF Z-5-CARBOXYMETHYLENE-1,3-DIOXOLAN-4-ONES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-03-16 | — | — | WO | disclosed |
| US-20060047129-A1 | Process for the preparation of Z-5-carboxymethylene-1,3-dioxolan-4-ones | BRISTOL-MYERS SQUIBB COMPANY | 2006-03-02 | — | — | US | disclosed |
| CN-1617849-A | HIV integrase inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2005-05-18 | — | — | CN | disclosed |
| US-6890942-B2 | Acyl sulfonamides as inhibitors of HIV integrase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-05-10 | — | — | US | disclosed |
| US-20050004232-A1 | Acyl sulfonamides as inhibitors of HIV integrase | BRISTOL-MYERS SQUIBB COMPANY | 2005-01-06 | — | — | US | disclosed |
| WO-2004103278-A2 | ACYL SULFONAMIDES AS INHIBITORS OF HIV INTEGRASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-12-02 | — | — | WO | disclosed |
| EP-1467695-A2 | HIV INTEGRASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2004-10-20 | — | — | EP | disclosed |
| US-6777440-B2 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-08-17 | — | — | US | disclosed |
| US-20040110804-A1 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-06-10 | — | — | US | disclosed |
| WO-2004004657-A2 | HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-01-15 | — | — | WO | disclosed |
| US-20030176495-A1 | HIV Integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2003-09-18 | — | — | US | disclosed |
| WO-2003049690-A2 | HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004232-A1 | Acyl sulfonamides as inhibitors of HIV integrase | ACSS2, ARSA, ASS1 | SRC 1175/4885PLA2G7 868/4885NFE2L2 4284/4885 |
| US-20040110804-A1 | HIV integrase inhibitors | CDKN1A, SAMHD1, CTCF | SRC 1543/4885PLA2G7 1180/4885NFE2L2 3546/4885 |
| US-20030176495-A1 | HIV Integrase inhibitors | MAPT, RIF1, HPRT1 | SRC 248/4885PLA2G7 4373/4885NFE2L2 4258/4885 |
| US-20060047129-A1 | Process for the preparation of Z-5-carboxymethylene-1,3-dioxolan-4-ones | TKT, KTN1, TET1 | SRC 2221/4885PLA2G7 3804/4885NFE2L2 4680/4885 |
| US-20130012546-A1 | FUNGICIDE HYDROXIMOYL-TETRAZOLE DERIVATIVES | HPD, HAAO, CYP8B1 | SRC 1841/4885PLA2G7 4105/4885NFE2L2 3528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.